Products
Renvistobart Biosimilar Monoclonal Antibody (TIGIT) for Research
Cat No.: GMP-Bios-INN-1363
Anti-TIGIT/WUCAM/VSTM3 therapeutic antibody (Pre-made Renvistobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Renvistobart (development code BMS-986207) is a monoclonal antibody targeting TIGIT. It is developed by Bristol-Myers Squibb and Compugen and Multiple Myeloma Research Consortium and Ono Pharmaceutical for Non-small cell lung cancer, Solid tumours, Multiple myeloma in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1363-1mg | 1mg | 3090 |
| GMP-Bios-INN-1363-10mg | 10mg | |
| GMP-Bios-INN-1363-100mg | 100mg | |
| GMP-Bios-INN-1363-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Renvistobart biosimilar, Whole mAb, Anti-TIGIT/WUCAM/VSTM3 Antibody: Anti-TIGIT/T-cell immunoreceptor with Ig and ITIM domains/V-set and immunoglobulin domain-containing protein 9/V-set and transmembrane domain-containing protein 3 therapeutic antibody |
| INN Name | Renvistobart |
| Target | TIGIT/WUCAM/VSTM3 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 8szy:HL:IM |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Bristol-Myers Squibb;Compugen;Multiple Myeloma Research Consortium;Ono Pharmaceutical |
| Conditions Approved | na |
| Conditions Active | Non-small cell lung cancer;Solid tumours;Multiple myeloma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
